Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.
Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
